- « Previous
- Clinical Pharmacology
- Next »
Mepron
Clinical Pharmacology
Mepron
Zidovudine: Data from 14 HIV- infected volunteers who were given atovaquone tablets 750 mg every 12 hours with zidovudine 200 mg every 8 hours showed a 24% ± 12% decrease in zidovudine apparent oral clearance, leading to a 35% ± 23% increase in plasma zidovudine AUC. The glucuronide metabolite: parent ratio decreased from a mean of 4.5 when zidovudine was administered alone to 3.1 when zidovudine was administered with atovaquone tablets. This effect is minor and would not be expected to produce clinically significant events. Zidovudine had no effect on atovaquone pharmacokinetics.
Relationship Between Plasma Atovaquone Concentration and Clinical Outcome: In a comparative study of atovaquone tablets with TMP- SMX for oral treatment of mild- to- moderate Pneumocystis carinii pneumonia (PCP) (see INDICATIONS AND USAGE), where AIDS patients received 750 mg atovaquone tablets three times daily for 21 days, the mean steady- state atovaquone concentration was 13.9 ± 6.9 mcg/ mL (n = 133). Analysis of these data established a relationship between plasma atovaquone concentration and successful treatment. This is shown in Table 2.
Table 2.
Relationship Between Plasma Atovaquone Concentration and Successful Treatment
| Steady- State Plasma Atovaquone Concentrations | Successful Treatment* (No. Successes/ No. in Group) (%) | |||
| (mcg/ mL) | Observed | Predicted † | ||
| 0 to <5 | 0/ 6 | (0%) | 1.5/ 6 | (25%) |
| 5 to <10 | 18/ 26 | (69%) | 14.7/ 26 | (57%) |
| 10 to <15 | 30/ 38 | (79%) | 31.9/ 38 | (84%) |
| 15 to <20 | 18/ 19 | (95%) | 18.1/ 19 | (95%) |
| 20 to <25 | 18/ 18 | (100%) | 17.8/ 18 | (99%) |
| 25+ | 6/ 6 | Brand Name: Mepron
Generic Name: Atovaquone
WebMD DailyGet breaking medical news. | ||
